Comments
Zydus Cadila has received final approval from the US health regulator to market candesartan cilexetil tablets used for the treatment of hypertension.
The company has received final nod from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 4 mg, 8 mg, 16 mg and 32 mg, Zydus Cadila said in a BSE filing today.
The company will manufacture the drug at its formulations manufacturing facility in Moraiya, Ahmedabad.
Zydus Cadila has more than 140 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Shares of the company’s listed entity, Cadila Healthcare, were trading 7.38 per cent up at Rs 496.65 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.